Pfizer Dividend of ₹165/Share: Ex-Date Today, July 9 – What You’ll Earn for 50 Shares?

Pfizer Limited's Board of Directors has declared and approved a final and special dividend of ₹165 per equity share of ₹10 each for the financial year ending March 31, 2025. 

Pfizer Dividend Record Date

The company's board of directors recommended a final dividend of ₹35 per equity share of ₹10 each (350%), along with two special dividends, ₹100 per share (1000%) to commemorate Pfizer’s 75 years in India and ₹30 per share (300%) in view of gains from the transfer of leasehold land and associated buildings.

This brings the total dividend for FY 2024–25 to ₹165 per equity share (1650%).The company has fixed July 9, 2025, as the record date to determine shareholders eligible for the final dividend.

How Much Will You Receive for Holding 50 Pfizer Shares?

If you own 50 shares of Pfizer Ltd, you’re in for a substantial dividend payout for the financial year ended March 31, 2025. The company has announced a total dividend of ₹165 per share, comprising a final dividend of ₹35, a ₹100 special dividend to commemorate Pfizer's 75th year in India, and an additional ₹30 special dividend from gains on asset transfer.

This means your total earnings from dividends alone would amount to ₹8,250 (₹165 x 50 shares), offering a return on your investment.

Also Read: Best Pharma Stocks in July 2025!

About Pfizer Ltd

Pfizer Ltd is involved in the manufacturing, marketing, trading, and export of pharmaceutical products. The company produces medicines at its own facility and also collaborates with several independent contract and third-party manufacturers across India. Its products are primarily distributed within the country through a network of independent distributors.

Conclusion 

The company's last dividend declaration was a final dividend of ₹35 per share, with a record date of August 21, 2024. With the newly approved dividend, shareholders can anticipate continued returns.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.